Eli Lilly is reportedly poised to finalize a substantial $2 billion deal with Hong Kong-based Insilico Medicine, a company specializing in artificial intelligence for drug discovery. The agreement, as reported by the Financial Times citing sources, would grant Eli Lilly exclusive rights to market a GLP-1 drug developed by Insilico Medicine for diabetes treatment. While Reuters has not yet independently verified the report, this potential acquisition underscores the growing trend of major pharmaceutical companies leveraging AI technologies to accelerate and enhance their drug development pipelines, particularly in the competitive field of metabolic diseases.